SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

MicroCloud Hologram, Inc. engages in research, development, and application of holographic technology. It operates through the Holographic Solutions and Holographic Technology Service segments. The company was founded in 2020 and is headquartered in New York, NY.

MicroCloud Hologram Inc

MicroCloud Hologram Inc. is trending due to significant price volatility, sparking intense debate among investors. The community is split between those hoping for a rebound and those warning of potential dilution or a pump and dump scheme. Discussions also include the company's financials, Bitcoin holdings and quantum computing prospects.

Memecoin on Cronos launched by the Cro Crow community

crow with knife

The crypto "crow with knife" ($CAW.X) is gaining traction, with community members actively chanting "caw caw" and highlighting its presence on multiple chains like Solana, Ethereum, and BNB. Discussion centers around its fully circulated supply, organic community growth, and unique burn mechanism. Some users suggest it's the only option in the meme coin space.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron is trending as investors anticipate its upcoming earnings report, with community discussions focused on forward guidance and potential market reactions. Several analysts have recently raised price targets, citing strong AI-driven demand and memory pricing, while others caution the stock may be priced for perfection. The broader context involves Micron's role in the semiconductor industry and its exposure to technology end markets.

BigBear.ai Holdings, Inc. engages in data-driven decision dominance and advanced analytics that provide its customers with a competitive advantage in a world driven by data that is growing in terms of volume, variety, and velocity. The firm operationalizes artificial intelligence and machine learning at scale through its end-to-end data analytics platform. It deploys its observe, orient and dominate products to customers throughout the defense, intelligence, and commercial markets. The company was founded in 2020 and is headquartered in McLean, VA.

BigBear.ai Holdings Inc

BigBear.ai is trending as community members discuss a potential short squeeze and speculate about new government contracts following news of a partnership with SMX to enhance maritime awareness for the U.S. Navy. Investors are closely watching key resistance levels, with many drawing comparisons to Palantir and anticipating significant long-term growth in the AI-driven defense sector. Recent price action and high trading volume have fueled bullish sentiment, although some caution about potential pullbacks and the company's financials.

"Shina Inu is a decentralized meme token on the Ethereum blockchain. Its mission is to give back to the crypto community, give to charity, and win the heart of the greatest token of all time, Shiba Inu!   Shina Token is a very fun meme token project that has sold many rare and beautiful NFTs. NFT sales are used to support the team and provide upcoming features such as exclusive access to events and rewards that will soon be announced."

Shina Inu

Shina Inu ($SHI.X) is trending amid community anticipation of an imminent breakout, fueled by strong accumulation signals and a tightening chart pattern. Bulls appear to be in control, citing consistent higher lows and increasing demand outweighing supply. Some users suggest the token could be the next big community-driven run.

United States Antimony Corp. engages in the extraction, processing and sale of antimony, zeolite, silver, and gold products. It operates through the following segments: United States Antimony Operations, Mexican Antimony Operations, Precious Metals Recovery, and United States Zeolite Operations. The company was founded by John C. Lawrence in June 1968 and is headquartered in Thompson Falls, MT.

United States Antimony Corp.

United States Antimony Corp

UAMY is trending as investors react to the news of a significant $245 million defense contract, viewing it as a potential catalyst for growth. The community is weighing the impact of this contract on the company's future, particularly its capacity to meet demand and its strategic position within the antimony market. Some are drawing parallels to other companies that have secured similar government contracts, while also keeping an eye on potential short squeezes.

Bollinger Innovations Inc. operates as an electric vehicle company, which engages in the manufacture of passenger electric vehicles and commercial vehicles. It operates through the Bollinger and Mullen/ELMS segments. The company was founded by David Michery on April 20, 2010 and is headquartered in Brea, CA.

Bollinger Innovations Inc.

Bollinger Innovations Inc

BINI is trending due to a recent reverse stock split, sparking intense debate about the company's future and potential for a short squeeze. The community is split between those hoping for a reversal and those anticipating further decline, with many citing past reverse splits and dilution concerns. Discussions also include the CEO and potential partnerships in the EV sector.

Ondas Holdings, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in Boston, MA.

Ondas Holdings Inc

Ondas Holdings is trending as investors react to its addition to the S&P Telecom Select Industry Index and a recent $3.5 million order for ground robotics. Community members are actively discussing the company's growth potential in the defense sector and its strategic acquisitions. Some traders are noting heavy options activity and expressing optimism about the stock's near-term prospects, while others highlight the importance of securing larger contracts to justify its valuation.

Cipher Mining, Inc. operates as a Bitcoin mining ecosystem in the United States. The firm is developing a cryptocurrency business. The company was founded in 2021 and is headquartered in New York, NY.

Cipher Mining Inc

Cipher Mining is trending as investors discuss potential hyperscale deals and the company's strategic positioning in the AI data center space, with some anticipating significant price appreciation. Community members are actively debating entry points, potential partnerships with major tech players, and the impact of broader market factors on the stock. The stock's movement is also being compared to sector peers like IREN and WULF.

Pagaya Technologies Ltd. engages in the development of AI and data networks for the financial industry. Its product deploys data science, machine learning and AI technology to evaluate the customers applications in real time. The company was founded by Gal Krubiner, Sanjiv Das, Yahav Yulzari, and Avital Pardo on March 20, 2016 and is headquartered in New York, NY.

Pagaya Technologies Ltd - Ordinary Shares - Class A

Pagaya Technologies Ltd

Pagaya Technologies is trending as investors debate its future amid market volatility and rising interest rates, with community members weighing whether it's a buying opportunity or a falling knife. Discussions also involve comparing Pagaya to competitors in the fintech space and the potential impact of upcoming economic reports and Fed decisions. Some traders are closely watching potential catalysts, including news of new partnerships and the upcoming Klarna IPO.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Aurinia (AUPH) Upgraded to Buy: Here's What You Should Know

Aurinia (AUPH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Aurinia Pharmaceuticals (AUPH) Q2 Earnings Miss Estimates

Aurinia (AUPH) delivered earnings and revenue surprises of -5.88% and +10.41%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Implied Volatility Surging for Aurinia Pharmaceuticals Stock Options

Investors need to pay close attention to AUPH stock based on the movements in the options market lately.

Retail chatter around Aurinia Pharmaceuticals picked up pace late Sunday, with investors eyeing an update on the company’s early-stage AUR200 trial targeting autoimmune conditions later in the day.The experimental therapy, first dosed in healthy volunteers in September 2024, is being evaluated in a single ascending dose study.&nbsp;The program is assessing safety, tolerability, drug behavior in the body, and biomarker response.&nbsp;AUR200 works by targeting both BAFF (B-cell Activating Factor) and APRIL (A Proliferation-Inducing Ligand), proteins involved in immune system regulation.&nbsp;The company has said it plans to pursue one broader indication and one rare disease, both with relatively few existing treatments.&nbsp;Funding for development is coming from Aurinia’s current cash flow.In May,&nbsp;<a href="https://stocktwits.com/symbol/AUPH">Aurinia</a> reported new findings from its Phase 3 AURORA 1 study of Lupkynis (voclosporin), its approved treatment for lupus nephritis.&nbsp;The post-hoc analysis suggested&nbsp;that patients receiving triple therapy with Lupkynis, mycophenolate mofetil (MMF), and low-dose steroids achieved better proteinuria outcomes than those on MMF and steroids alone.&nbsp;&nbsp;Adverse event rates were comparable between groups.On Stocktwits, retail sentiment for <a href="https://stocktwits.com/symbol/AUPH">Aurinia Pharmaceuticals</a> was ‘extremely bullish’ amid ‘extremely high’ message volume.One user said they wouldn’t be selling even if the stock hit $10, saying they were “in it for the big bucks.”&nbsp;<stembedurl>https://stocktwits.com/RedBarnCannabis/message/619401660</stembedurl>Another pointed out that historically, strong data has moved the stock significantly and stated that with Aurinia’s sizable cash reserves, dilution concerns were minimal, adding that they were hoping for double-digit gains following the update.<stembedurl>https://stocktwits.com/timfris/message/619390483</stembedurl>The stock has declined 1.5% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Retail Bulls Charge Into Aurinia Pharmaceuticals Ahead Of Autoimmune Trial Results

AUR200 targets both BAFF and APRIL, which are key immune system proteins. It is being developed for one large indication and one rare disease.

Equity

Aurinia (AUPH) Surges 7.5%: Is This an Indication of Further Gains?

Aurinia (AUPH) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Is the Options Market Predicting a Spike in Aurinia Pharmaceuticals (AUPH) Stock?

Company News for May 13, 2025

Shares of Aurinia Pharmaceuticals Inc. (AUPH) surged 3% in premarket trading on Monday after the company’s first-quarter (Q1) earnings topped Wall Street expectations.The biopharmaceutical company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.businesswire.com/news/home/20250512965572/en/Aurinia-Pharmaceuticals-Reports-Financial-Results-for-the-Three-Months-Ended-March-31-2025">reported</a> a 24% year-on-year (YoY) jump in its first-quarter (Q1) total revenue to $62.5 million, surpassing an analyst estimate of $61.06 million, according to Finchat data.The surge in revenue was primarily driven by a 25% YoY jump in net product sales of Lupkynis, the company’s FDA-approved oral therapy for treating adult patients with active lupus nephritis, to $60 million.For the three months ending March 31, 2025, the company reported a net income of $23.3 million, compared to a loss of $10.7 million in 2024.Diluted earnings per share came in at $0.16 for the quarter, compared to a loss of $0.07 per share recorded in the corresponding period of 2024, and above an analyst estimate of $0.1. &nbsp;&nbsp;&nbsp;&nbsp;Aurinia ended the quarter with cash, cash equivalents, restricted cash, and investments of $312.9 million, compared to $358.5 million on Dec. 31, 2024.CEO Peter Greenleaf said the company looks forward to a “strong performance” in 2025.The firm also reiterated its full-year total revenue guidance of $250 million to $260 million and net product sales guidance of $240 million to $250 million.On Stocktwits, retail sentiment around Aurinia jumped from ‘bearish’ to ‘neutral’ territory over the past 24 hours while message volume stayed at ‘normal’ levels.<figure class="image"><img style="aspect-ratio:632/60;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_12_at_7_28_54_AM_png_b95ef3aeed.webp" alt="AUPH's Sentiment Meter and Message Volume as of 7:30 a.m. ET on May 12, 2025 | Source: Stocktwits" width="632" height="60"><figcaption>AUPH's Sentiment Meter and Message Volume as of 7:30 a.m. ET on May 12, 2025 | Source: Stocktwits</figcaption></figure> <a href="https://stocktwits.com/symbol/AUPH">AUPH stock</a> is down by about 9% this year but up by over 59% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/expedia-retail-traders-remain-optimistic-despite-q1-revenue-miss/chiNeqjRbme">Expedia Retail Traders Remain Optimistic Despite Q1 Revenue Miss Ahead Of Holiday Travel Season</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Aurinia Stock Rallies On Upbeat Q1 Earnings, CEO Expects Strong Performance in 2025: Retail Sentiment Brightens

The company also reiterated its full-year total revenue guidance of $250 million to $260 million and net product sales guidance of $240 million to $250 million.

Biotech stocks are a hot-button topic for retail investors on Stocktwits, where over&nbsp;four million users track these companies, hoping to spot the next big therapeutic breakthrough.Two names currently trending in the space are Mainz Biomed, a molecular genetics cancer diagnostic company based in Germany, and Aurinia Pharmaceuticals Inc., a Canadian biopharmaceutical firm focused on autoimmune disease treatments.Over the past three months, Mainz has seen a staggering 2,500% increase in message volume on Stocktwits, while Aurinia’s engagement has grown just 23%.&nbsp;However, Aurinia maintains nearly three times the following of Mainz on the platform.&nbsp;A recent Stocktwits poll of over 1,100 respondents found that 53% believe Mainz offers more upside, compared to 34% favoring Aurinia.<figure class="image"><img style="aspect-ratio:1294/736;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/MYNZ_vs_AUPH_poll_as_of_March_6_43ea585c2e.png" alt="MYNZ vs AUPH poll as of March 6.png" width="1294" height="736"><figcaption>MYNZ vs AUPH poll as of March 6. | source: Stocktwits</figcaption></figure>Maxim Group recently initiated coverage on Mainz with a ‘Buy’ rating and a $14 price target, highlighting its role in the $4 billion colorectal cancer screening market.&nbsp;The firm is optimistic about Mainz’s next-generation test, which uses mRNA biomarkers to improve the detection of pre-cancerous adenomas and potentially enhance colorectal cancer prevention.&nbsp;Mainz is conducting a clinical study on this test, with data expected in the second half of 2025, and plans to finalize protocols for a pivotal U.S. study in 2026.In October, Mainz reported fiscal first-half loss per share had narrowed to $0.48 from $1 a year earlier, with revenue rising to $520,773 from $499,049.&nbsp;The company’s cash and cash equivalents stood at $977,764.Retail traders on Stocktwits have pointed to increasing institutional investment in Mainz, with funds such as Artisan Mid Cap Fund reportedly raising their stakes.&nbsp;<stembedurl>https://stocktwits.com/CarterWood/message/607119518</stembedurl>Some traders speculate that Mainz could see significant catalysts, including an upcoming product launch, a potential partnership, accelerated clinical progress, or an FDA resubmission with fast-track approval.<stembedurl>https://stocktwits.com/FosterD_Nightfall/message/607091090</stembedurl>Aurinia, in contrast, has gained attention for its development of AUR200, a therapy targeting BAFF (B-cell Activating Factor) and APRIL (A Proliferation-Inducing Ligand). The company believes this could become a best-in-class treatment for autoimmune diseases.&nbsp;It has already commercialized Lupkynis, the first FDA-approved oral therapy for adult patients with active lupus nephritis.In its latest financial report, Aurinia posted fourth-quarter earnings of $0.01 per diluted share, a sharp turnaround from a $0.19 loss a year earlier and better than analysts’ projected $0.02 per-share loss.&nbsp;Revenue for the quarter rose to $59.9 million from $45.1 million a year earlier but fell slightly below Wall Street estimates of $60.1 million.&nbsp;For 2025, Aurinia forecasts revenue between $250 million and $260 million, trailing the $274.4 million expected by analysts.Last year, Aurinia said it would <a href="https://stocktwits.com/news-articles/markets/equity/auph-stock-surges-on-insider-buying/cJa2dg8Rin">strengthen</a> its financial position by cutting nearly half its staff to save over $40 million annually.&nbsp;The company also made leadership changes, including CEO Peter Greenleaf’s conditional resignation as a director.&nbsp;As of Dec. 31, 2024, Aurinia held cash, cash equivalents, and investments totaling $358.5 million, up slightly from $350.7 million a year earlier.According to Koyfin data, short interest in Aurinia stood at 7%, compared to 5.1% for Mainz.&nbsp;Over the past year, Aurinia shares have gained more than 44%, though they are down over 9% year-to-date.&nbsp;Mainz, meanwhile, has fallen more than 86% in the past 12 months but has rebounded over 25% since the start of this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Mainz Biomed Vs. Aurinia Pharma: Retail Traders Weigh In On The Better Biotech Bet

Over the past three months, Mainz has seen a staggering 2,500% increase in message volume on Stocktwits, while Aurinia’s engagement has grown just 23%. 

Aurinia Pharmaceuticals to Release 2024 Fourth Quarter and Full Year Financial and Operational Results on February 27, 2025

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will release 2024 fourth quarter and full year financial and operational results before markets open on...

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

$BBAI

$BETR

$OPEN

$IONQ

Which of these trending stocks are you most bullish on for the next 5 years?

Current Price	$13.09
Prev Close	$13.07
Open	$13.03
Dividend Yield	0.00%
50-Day Moving Average	$11.23
Beta	1.00
Avg. Volume	2.51M
PE Ratio	30.57

52-Week High	$13.44
52-Week Low	$6.55
Market Capitalization	$1.72B
EPS (Annual)	$0.0393
Price to Book	5.17
Revenue Per Employee	$1.81M
Enterprise Value/EBITDA	N/A

AUPH
Aurinia Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest AUPH News

AUPH Aurinia Pharmaceuticals Inc